Published in Cancer Clin Trials on January 01, 1981
Newly recognized syndrome in the neck. J R Soc Med (1983) 1.29
Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer (1990) 1.07
Plasma TGF-beta1-related survival of postmenopausal metastatic breast cancer patients. Clin Exp Metastasis (2004) 0.92
Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J (Clin Res Ed) (1983) 0.89
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. Br J Cancer (1995) 0.75
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40
Sudden death in cancer patient on high-dose domperidone. Lancet (1982) 1.60
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep (1978) 1.51
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol (1999) 1.47
Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood (1992) 1.36
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med (1987) 1.30
Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol (1994) 1.29
Analysis of somatic mutations at human minisatellite loci in tumors and cell lines. Genomics (1989) 1.28
Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J Clin Invest (1995) 1.25
Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer (1985) 1.23
New agents in non-small cell lung cancer. Cancer Treat Rev (1984) 1.19
Unfavourable effects of long-term adjuvant chemotherapy with Endoxan in radically operated bronchogenic carcinoma. Eur J Cancer (1971) 1.13
Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol (1994) 1.10
Epstein-Barr virus-associated anaplastic large cell lymphoma in renal transplant patients. Am J Clin Pathol (1992) 1.10
Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ (2007) 1.09
Assessment of clonality in human tumors: a review. Cancer Res (1990) 1.08
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene (2012) 1.08
Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene (2006) 1.06
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1997) 1.04
Induction of Bim limits cytokine-mediated prolonged survival of neutrophils. Cell Death Differ (2009) 0.99
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene (1998) 0.99
A myeloperoxidase cDNA clone identifies an EcoRV RFLP. Nucleic Acids Res (1990) 0.97
Combined chemo- and hormonal therapy in advanced breast cancer. Cancer (1977) 0.93
DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function. Oncogene (2008) 0.93
PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity. Oncogene (2008) 0.93
Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res (1999) 0.92
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun (2000) 0.92
A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol (1999) 0.91
The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1. Leukemia (2010) 0.91
Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol (2001) 0.91
Primary or secondary extragonadal germ cell tumors? J Urol (1986) 0.90
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol (1997) 0.89
Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J (Clin Res Ed) (1983) 0.89
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol (2001) 0.89
A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment. Cancer Treat Rep (1978) 0.89
Psychogenic purpura, idiopathic thrombocytopenic purpura, and platelet dysfunction in the same patient. J Clin Psychiatry (1986) 0.89
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol (1999) 0.88
Factors associated with transfusion requirements during treatment for acute myelogenous leukemia. Ann Hematol (1993) 0.88
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer (2004) 0.88
Present and future projects of the International Breast Cancer Study Group. Cancer (1994) 0.86
Coagulation markers predict survival in cancer patients. Thromb Haemost (2002) 0.86
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (1998) 0.86
Clonal X-inactivation analysis of human tumours using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue. Mol Cell Probes (1997) 0.86
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol (2002) 0.85
Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood (1993) 0.85
[The oral administration of vitamin-A-acid in leukoplakias, hyperkeratoses and squamous cell carcinomas: results and tolerance]. Schweiz Med Wochenschr (1971) 0.85
Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells. Leukemia (1997) 0.85
Somatic mutations detected by mini- and microsatellite DNA markers reveal clonal intratumor heterogeneity in gastrointestinal cancers. Cancer Res (1995) 0.85
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Bone Marrow Transplant (1999) 0.84
Expression of TCL1 in hematologic disorders. Pathobiology (2001) 0.84
Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-26271) for radically resected bronchogenic carcinoma. Cancer Chemother Rep 3 (1973) 0.84
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2000) 0.84
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther (1986) 0.84
Spontaneous massive abdominal wall hematoma in polycythemia vera. Acta Haematol (1985) 0.84
Frequent clonal loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias. Blood (1996) 0.84
Different p16INK4a and p14ARF expression patterns in acute myeloid leukaemia and normal blood leukocytes. Leuk Lymphoma (2001) 0.83
Studying clonal heterogeneity in human cancers. Cancer Res (1993) 0.83
Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. Int J Cancer (2000) 0.83
Treatment of metastatic testicular carcinoma with bleomycin (NSC-125066) used alone or in combination with CCNU (NSC-79037). Cancer Chemother Rep (1975) 0.83
Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine. Cancer (1976) 0.83
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol (1991) 0.82
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (1997) 0.82
The two faces of p73. Cell Death Differ (2002) 0.82
Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab (1993) 0.82
Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab (1994) 0.82
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC). Int J Cancer (1992) 0.81
The cyclin-dependent kinase inhibitors p18INK4c and p19INK4d are highly expressed in CD34+ progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells. Br J Haematol (1999) 0.81
New drugs in small-cell lung cancer. Cancer Treat Rev (1986) 0.81
[Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer]. Schweiz Med Wochenschr (1982) 0.81
Clonal loss of heterozygosity in microdissected Hodgkin and Reed-Sternberg cells. J Natl Cancer Inst (1999) 0.81
The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry. Ann Oncol (2007) 0.81
Invasion depth is the most important prognostic factor for transitional-cell carcinoma in a prospective trial of radical cystectomy and adjuvant chemotherapy. Int J Cancer (1994) 0.81
Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol (1993) 0.80
Patterns of drug resistance parameters in adult leukemia. Leuk Lymphoma (1995) 0.80
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol (2008) 0.80
Short- or long-term chemotherapy for node-positive breast cancer: LMF 6 versus 18 cycles. SAKK study 27/76. Recent Results Cancer Res (1984) 0.80
A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs (1984) 0.79
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. Ann Oncol (1990) 0.79
[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71]. Schweiz Med Wochenschr (1980) 0.79
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer (1999) 0.79
Interleukin-8 expression by fetal and neonatal pulmonary cells in hyaline membrane disease and amniotic infection. Pediatr Res (2000) 0.79
IgG2 and IgG4 subclass deficiency and Evan's syndrome in an adult patient. J Allergy Clin Immunol (1992) 0.79
[Colorectal cancer. Progress and unsolved problems]. Schweiz Med Wochenschr (1981) 0.79
[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. Schweiz Med Wochenschr (1989) 0.78
Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol (1997) 0.78
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Med Pediatr Oncol (1979) 0.78